about
DNAApp: a mobile application for sequencing data analysis.A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2.A comparison and optimization of methods and factors affecting the transformation of Escherichia coli.Comparison of customized spin-column and salt-precipitation finger-prick blood DNA extraction.The role of Antibody Vκ Framework 3 region towards Antigen binding: Effects on recombinant production and Protein L binding.Fast reversible single-step method for enhanced band contrast of polyacrylamide gels for automated detection.Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding.Role of FcαR EC2 region in extracellular membrane localization.Effect of VH-VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding.Perspective: The promises of a holistic view of proteins-impact on antibody engineering and drug discoveryAllosteric Effects between the Antibody Constant and Variable Regions: A Study of IgA Fc Mutations on Antigen BindingAuthor Correction: The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-bindingThe Determination of HIV-1 RT Mutation Rate, Its Possible Allosteric Effects, and Its Implications on Drug ResistanceNot all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and TrastuzumabProbability of change in life: Amino acid changes in single nucleotide substitutionsReviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor DesignsRole of the IgE variable heavy chain in FcεRIα and superantigen binding in allergy and immunotherapy
P50
Q30840848-31D52FBB-87C9-45F5-B82A-8270C16E94D1Q33914759-7F823D60-CA8A-4120-9850-5E96E956C0B8Q34384973-F888DCC2-136C-4E41-9224-A6661BA84D77Q34438756-80B87213-A1EE-4ACE-870C-BDA7A0C9D12EQ41094963-9BE5DE24-7D6B-4C62-A058-800BF978E551Q43139857-BE70AD96-5266-4CBA-88FC-FE00E2AC93BCQ47252759-FC1812B7-7109-4B76-BC20-E6EACE5267FDQ47731094-890AAA5A-7D11-4632-B840-D6948BCEBEEEQ52724150-E639BCA3-4E00-43F5-9B4A-CB8956FF5520Q54941485-2CD6E6F8-C8D6-46A3-A6B1-F3B7E678B199Q64236704-F18B8BAA-7EF8-4A1B-9A74-4C8B1380230BQ90212270-AC41CED8-194C-47FC-897E-F1F89E0B27DEQ90295877-83EDB756-1C9A-4B38-BA07-0D4DB7BF2092Q90395045-40638EAA-B58E-45FD-AD45-FA25887096CFQ90609780-E9A9D02C-CE9A-4E92-AF7A-FDB551A7441FQ91662761-F483BD69-C65D-4860-BEF3-B157A685DC22Q93140697-952D709B-9D8C-41FD-AB3B-CD67EA386C37Q93158024-FC898561-BDA5-486C-9B9C-4801910B2911
P50
description
investigador
@es
researcher
@en
name
Samuel Ken-En Gan
@en
type
label
Samuel Ken-En Gan
@en
prefLabel
Samuel Ken-En Gan
@en
P31
P496
0000-0001-9936-5090